US Stock Insider Trading | Lyell Immunopharma Disclosed 2 Insider Transactions on March 9

K-LinePoet · 2026-03-15T14:29:21+00:00

Lyell Immunopharma recently disclosed insider trading information. ARCH Venture Partners IX, LLC purchased 480,100 shares on March 6, 2026. Additionally, executives and directors conducted multiple sell transactions on and before February 11. The company focuses on cell therapy for hematologic malignancies and solid tumors, with anticipated entry into pivotal trials in 2025.

K-LinePoet

2026-03-15 14:29:21

Abstract generation in progress

On March 9, 2026, Lyell Immunopharma (LYEL) disclosed two insider trading transactions. A shareholder holding more than 10%, ARCH Venture Partners IX, LLC, purchased 488,100 shares on March 6, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 9, 2026	Shareholder >10%	ARCH Venture Fund XIII, L.P., ARCH Venture Partners IX, LLC	March 6, 2026	Buy	488,100	25.61	25,000,000
February 12, 2026	Executive	Hill Stephen J.	February 11, 2026	Sell	1,236	23.39	23,290
February 12, 2026	Executive	Lee Gary K.	February 11, 2026	Sell	1,671	23.39	38,900
February 12, 2026	Director	Seely Lynn	February 11, 2026	Sell	7,455	23.39	174,400
February 11, 2026	Executive	Hill Stephen J.	February 10, 2026	Sell	109	23.12	2,520
February 11, 2026	Director	Seely Lynn	February 10, 2026	Sell	438	23.12	11,000
February 11, 2026	Executive	Veronica Sanchez Bulis	February 10, 2026	Sell	254	23.12	5,872
February 11, 2026	Executive	Lee Gary K.	February 10, 2026	Sell	147	23.12	3,399
January 6, 2026	Executive	Veronica Sanchez Bulis	December 30, 2025	Sell	936	32.32	30,300
January 6, 2026	Executive	Veronica Sanchez Bulis	December 24, 2025	Sell	1,136	38.67	43,900

【Company Profile】

Lyell Immunopharma, Inc. was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy firm expected to enter pivotal trials in 2025, advancing proprietary next-generation autologous CAR T-cell candidate pipelines for hematologic malignancies and solid tumors. The company is pioneering new approaches to generate T cells that drive durable clinical responses. Patient’s live cells are the starting point for the company’s research-based CAR T-cell therapies, enhanced through innovative CAR structures, technologies, and manufacturing protocols.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.